サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1388188

口腔乾燥症治療薬市場、シェア、規模、動向、産業分析レポート：タイプ別、製品別、地域別、セグメント別予測、2023年～2032年

Xerostomia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Type (OTC, Prescription), By Product, By Region, And Segment Forecasts, 2023 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 115 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
口腔乾燥症治療薬市場、シェア、規模、動向、産業分析レポート：タイプ別、製品別、地域別、セグメント別予測、2023年～2032年
出版日: 2023年10月23日
発行: Polaris Market Research
ページ情報: 英文 115 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris market researchの最新調査によると、口腔乾燥症治療薬の世界市場規模は2032年までに29億4,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

口腔乾燥症製品に対する有利な償還政策、つまり、口腔乾燥症の治療が必要な患者は、費用の一部が保険やヘルスケアプランでカバーされるため、これらの製品をより簡単に、低コストで入手することができます。このことは、患者が治療を受けることを促し、最終的に口腔乾燥症関連製品や医薬品の需要を促進します。口腔乾燥症は、シェーグレン症候群、糖尿病、高血圧、パーキンソン病などの基礎疾患の症状や副作用であることが多いです。

これらの疾患に対する認識が医療従事者や一般の人々の間で高まるにつれ、より多くの症例が診断・治療されるようになっています。医療従事者はこれらの基礎疾患を持つ患者のドライマウス症状を特定し、対処する可能性が高くなるためです。例えば、Colgate-Palmolive CompanyやSjogren Syndrome Foundation of Americaのような組織が提供する統計は、米国における口腔乾燥症と関連疾患の有病率を強調しています。これらの数字は、効果的な治療法の必要性と、より大きな健康上の懸念の症状として口腔乾燥症に対処することの重要性を強調しています。

シェーグレン症候群財団は、シェーグレン症候群の認知度を高め、口腔乾燥を伴うことの多いシェーグレン症候群患者を支援するために活動しています。同財団は、米国とカナダの両方で、この自己免疫疾患に苦しむ人々を支援し、啓発プログラムを実施しています。2017年までにシェーグレン症候群の診断にかかる期間を2.5年未満に短縮することを目的とした「5-Year Breakthrough Goal」を導入。これにより、シェーグレン症候群の診断と治療を迅速化し、包括的なケアプランの一環として口腔乾燥の問題に対処することを目指しました。

さらに、この市場の大手企業は、新興企業の買収と啓発プログラムの実施の重要性を認識しています。例えば、Orajel社はiCrossing社と共同でキャンペーンを開始しました。このキャンペーンの目的は、口腔乾燥症のような問題への対処を含む口腔ケアの重要性について親を教育することでした。口腔の健康やドライマウスのような症状について一般の人々を教育することで、このような取り組みは口腔乾燥症やその治療法についての認識を高めることに貢献しています。

口腔乾燥症治療薬市場レポートハイライト

OTC薬セグメントは、入手が容易で価格も手ごろであり、有効率も高いことから、市場を独占しています。

歯磨剤セグメントは、必須の唾液成分、カルシウム、リン酸塩を回復することによって唾液刺激剤を改善することに焦点を当てており、より効率的であるため、急速に成長すると予想されます。

北米が最大のシェアを占めていますが、これは主に口腔乾燥症の弊害に関する患者の意識と、発達した医療インフラによる効果的な治療オプションによるものです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の口腔乾燥症治療薬市場に関する洞察

  • 口腔乾燥症治療薬市場- 業界スナップショット
  • 口腔乾燥症治療薬市場力学
    • 促進要因と機会
      • 口腔の健康状態の有病率の増加
      • 緩和ケアと支持療法の需要の高まり
    • 抑制要因と課題
      • 一部の口腔乾燥症治療薬の副作用
  • PESTLE分析
  • 口腔乾燥症治療薬業界の動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界の口腔乾燥症治療薬市場、製品別

  • 主な調査結果
  • イントロダクション
  • 唾液刺激剤
  • 唾液代替品
  • 歯磨剤

第6章 世界の口腔乾燥症治療薬市場、タイプ別

  • 主な調査結果
  • イントロダクション
  • OTC薬
  • 処方薬

第7章 世界の口腔乾燥症治療薬市場、地域別

  • 主な調査結果
  • イントロダクション
    • 口腔乾燥症治療薬市場評価、地域別、2019-2032年
  • 口腔乾燥症治療薬市場-北米
    • 北米：口腔乾燥症治療薬市場、タイプ別、2019-2032年
    • 北米：口腔乾燥症治療薬市場、製品別、2019-2032年
    • 口腔乾燥症治療薬市場-米国
    • 口腔乾燥症治療薬市場- カナダ
  • 口腔乾燥症治療薬市場- 欧州
    • 欧州：口腔乾燥症治療薬市場、種類別、2019～2032年
    • 欧州：口腔乾燥症治療薬市場、製品別、2019～2032年
    • 口腔乾燥症治療薬市場- 英国
    • 口腔乾燥症治療薬市場- フランス
    • 口腔乾燥症治療薬市場- ドイツ
    • 口腔乾燥症治療薬市場- イタリア
    • 口腔乾燥症治療薬市場- スペイン
    • 口腔乾燥症治療薬市場- オランダ
    • 口腔乾燥症治療薬市場- ロシア
  • 口腔乾燥症治療薬市場- アジア太平洋
    • アジア太平洋：口腔乾燥症治療薬市場、種類別、2019～2032年
    • アジア太平洋：口腔乾燥症治療薬市場、製品別、2019～2032年
    • 口腔乾燥症治療薬市場- 中国
    • 口腔乾燥症治療薬市場- インド
    • 口腔乾燥症治療薬市場- マレーシア
    • 口腔乾燥症治療薬市場- 日本
    • 口腔乾燥症治療薬市場- インドネシア
    • 口腔乾燥症治療薬市場- 韓国
  • 口腔乾燥症治療薬市場-中東およびアフリカ
    • 中東およびアフリカ：口腔乾燥症治療薬市場、種類別、2019～2032年
    • 中東およびアフリカ：口腔乾燥症治療薬市場、製品別、2019～2032年
    • 口腔乾燥症治療薬市場- サウジアラビア
    • 口腔乾燥症治療薬市場-UAE
    • 口腔乾燥症治療薬市場- イスラエル
    • 口腔乾燥症治療薬市場- 南アフリカ
  • 口腔乾燥症治療薬市場-ラテンアメリカ
    • ラテンアメリカ：口腔乾燥症治療薬市場、タイプ別、2019-2032年
    • ラテンアメリカ：口腔乾燥症治療薬市場、製品別、2019-2032年
    • 口腔乾燥症治療薬市場- メキシコ
    • 口腔乾燥症治療薬市場- ブラジル
    • 口腔乾燥症治療薬市場- アルゼンチン

第8章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Acacia Pharma
  • Church & Dwight Co., Inc.
  • Colgate-Palmolive Company
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Lupin Pharmaceuticals, Inc.
  • OraCoat
  • Parnell Pharmaceuticals, Inc.
  • Pendopharm
  • Pfizer, Inc.
  • Sun Pharmaceuticals Industries Ltd.
図表

List of Tables

  • Table 1 Global Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 3 Xerostomia Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 5 North America: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 6 U.S.: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 7 U.S.: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 8 Canada: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 9 Canada: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 10 Europe: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 11 Europe: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 12 UK: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 13 UK: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 14 France: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 15 France: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 16 Germany: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 17 Germany: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 18 Italy: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 19 Italy: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 20 Spain: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 21 Spain: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 24 Russia: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 25 Russia: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 28 China: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 29 China: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 30 India: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 31 India: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 34 Japan: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 35 Japan: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 38 South Korea: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 39 South Korea: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 44 UAE: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 45 UAE: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 46 Israel: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 47 Israel: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 48 South Africa: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 49 South Africa: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 50 Latin America: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Latin America: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 52 Mexico: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 53 Mexico: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 54 Brazil: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 55 Brazil: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 56 Argentina: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • Table 57 Argentina: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Xerostomia Therapeutics Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Type
  • Figure 7 Global Xerostomia Therapeutics Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Product
  • Figure 9 Global Xerostomia Therapeutics Market, by Product, 2022 & 2032 (USD Billion)
  • Figure 10 Xerostomia Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Xerostomia Therapeutics Market
目次
Product Code: PM1339

The global xerostomia therapeutics market size is expected to reach USD 2.94 billion by 2032, according to a new study by Polaris market research. The report "Xerostomia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Type (OTC, Prescription), By Product, By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Favorable reimbursement policies for xerostomia products. This means that individuals who require treatment for xerostomia can access these products more easily and at reduced costs, as a portion of their expenses is covered by insurance or healthcare plans. This encourages patients to seek treatment, ultimately driving the demand for xerostomia-related products and medications. Xerostomia is often a symptom or side effect of underlying conditions such as Sjogren's syndrome, diabetes, hypertension, and Parkinson's disease.

As awareness of these diseases increases among both healthcare professionals and the general population, more cases are being diagnosed and treated. This, in turn, has a positive impact on the demand for xerostomia treatments, as healthcare providers are more likely to identify and address dry mouth symptoms in patients with these underlying conditions. For instance, statistics provided by organizations like Colgate-Palmolive Company and the Sjogren Syndrome Foundation of America highlight the prevalence of xerostomia and related diseases in the United States. These figures underscore the need for effective treatments and the importance of addressing xerostomia as a symptom of larger health concerns.

Sjogren Syndrome Foundation of America's efforts to create awareness and support patients affected by Sjogren's syndrome, a condition often accompanied by xerostomia. The foundation conducts awareness programs and aids individuals suffering from this autoimmune disorder in both the United States & Canada. Introduced "5-Year Breakthrough Goal" with the objective of reducing the time it takes to diagnose the condition to less than 2.5 years by 2017. By doing so, they aimed to expedite the diagnosis and treatment of Sjogren's syndrome, which often includes addressing the issue of xerostomia as part of the comprehensive care plan.

Additionally, major players in the market recognize the importance of both acquiring emerging companies and conducting awareness programs. For instance, Orajel initiated a campaign in collaboration with iCrossing; the goal of this campaign was to educate parents about the significance of oral care, which includes addressing issues like xerostomia. By educating the public about oral health and conditions like dry mouth, these initiatives contribute to increasing awareness about xerostomia and its treatment options.

Xerostomia Therapeutics Market Report Highlights

The OTC segment dominated the market, as they are easily available, affordable, and have a higher efficacy rate

The dentifrices segment will grow rapidly, as they are more efficient as they focus on improving the salivary stimulants by restoring essential salivary components, Calcium, and phosphate

North America held the largest share, primarily due to patient awareness regarding the ill effects of xerostomia, effective treatment options via its well-developed medical infrastructure

The key market players include GlaxoSmithKline, Hikma Pharmaceuticals, Pendopharm, Sun Pharma, Lupin Pharmaceuticals, and Pfizer

Polaris market research has segmented the xerostomia therapeutics market report based on type, product, and region:

Xerostomia Therapeutics, Type Outlook (Revenue - USD Billion, 2023 - 2032)

  • OTC
  • Prescription

Xerostomia Therapeutics, Product Outlook (Revenue - USD Billion, 2023 - 2032)

  • Salivary Stimulants
  • Salivary Substitutes
  • Dentifrices

Xerostomia Therapeutics, Regional Outlook (Revenue - USD Billion, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Xerostomia Therapeutics Market Insights

  • 4.1. Xerostomia Therapeutics Market - Industry Snapshot
  • 4.2. Xerostomia Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increased prevalence of oral health conditions
      • 4.2.1.2. Growing demand for palliative care and supportive therapies
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Side effects of some xerostomia medications
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Xerostomia Therapeutics Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Xerostomia Therapeutics Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Xerostomia Therapeutics, by Product, 2019-2032 (USD Billion)
  • 5.3. Salivary Stimulants
    • 5.3.1. Global Xerostomia Therapeutics Market, by Salivary Stimulants, by Region, 2019-2032 (USD Billion)
  • 5.4. Salivary Substitutes
    • 5.4.1. Global Xerostomia Therapeutics Market, by Salivary Substitutes, by Region, 2019-2032 (USD Billion)
  • 5.5. Dentifrices
    • 5.5.1. Global Xerostomia Therapeutics Market, by Dentifrices, by Region, 2019-2032 (USD Billion)

6. Global Xerostomia Therapeutics Market, by Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
  • 6.3. OTC
    • 6.3.1. Global Xerostomia Therapeutics Market, by OTC, by Region, 2019-2032 (USD Billion)
  • 6.4. Prescription
    • 6.4.1. Global Xerostomia Therapeutics Market, by Prescription, by Region, 2019-2032 (USD Billion)

7. Global Xerostomia Therapeutics Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Xerostomia Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Xerostomia Therapeutics Market - North America
    • 7.3.1. North America: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
    • 7.3.2. North America: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.3.3. Xerostomia Therapeutics Market - U.S.
      • 7.3.3.1. U.S.: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.3.4. Xerostomia Therapeutics Market - Canada
      • 7.3.4.1. Canada: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • 7.4. Xerostomia Therapeutics Market - Europe
    • 7.4.1. Europe: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.3. Xerostomia Therapeutics Market - UK
      • 7.4.3.1. UK: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.4. Xerostomia Therapeutics Market - France
      • 7.4.4.1. France: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.5. Xerostomia Therapeutics Market - Germany
      • 7.4.5.1. Germany: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.6. Xerostomia Therapeutics Market - Italy
      • 7.4.6.1. Italy: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.7. Xerostomia Therapeutics Market - Spain
      • 7.4.7.1. Spain: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.8. Xerostomia Therapeutics Market - Netherlands
      • 7.4.8.1. Netherlands: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.9. Xerostomia Therapeutics Market - Russia
      • 7.4.9.1. Russia: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • 7.5. Xerostomia Therapeutics Market - Asia Pacific
    • 7.5.1. Asia Pacific: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.3. Xerostomia Therapeutics Market - China
      • 7.5.3.1. China: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.4. Xerostomia Therapeutics Market - India
      • 7.5.4.1. India: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.5. Xerostomia Therapeutics Market - Malaysia
      • 7.5.5.1. Malaysia: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.6. Xerostomia Therapeutics Market - Japan
      • 7.5.6.1. Japan: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.7. Xerostomia Therapeutics Market - Indonesia
      • 7.5.7.1. Indonesia: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.8. Xerostomia Therapeutics Market - South Korea
      • 7.5.8.1. South Korea: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • 7.6. Xerostomia Therapeutics Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.3. Xerostomia Therapeutics Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.4. Xerostomia Therapeutics Market - UAE
      • 7.6.4.1. UAE: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.5. Xerostomia Therapeutics Market - Israel
      • 7.6.5.1. Israel: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.6. Xerostomia Therapeutics Market - South Africa
      • 7.6.6.1. South Africa: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • 7.7. Xerostomia Therapeutics Market - Latin America
    • 7.7.1. Latin America: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.3. Xerostomia Therapeutics Market - Mexico
      • 7.7.3.1. Mexico: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.4. Xerostomia Therapeutics Market - Brazil
      • 7.7.4.1. Brazil: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.5. Xerostomia Therapeutics Market - Argentina
      • 7.7.5.1. Argentina: Xerostomia Therapeutics Market, by Type, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Xerostomia Therapeutics Market, by Product, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Acacia Pharma
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Church & Dwight Co., Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Colgate-Palmolive Company
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. GlaxoSmithKline plc
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Hikma Pharmaceuticals PLC
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Lupin Pharmaceuticals, Inc.
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. OraCoat
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Parnell Pharmaceuticals, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Pendopharm
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Pfizer, Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Sun Pharmaceuticals Industries Ltd.
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development